Concepedia

Justin L. Ricker

JL

37

Publications

6.4K

Citations

25

H-Index

2000

Active since

Affiliations

The University of Texas MD Anderson Cancer Center(Current)

AbbVie (United States)

Merck & Co., Inc., Rahway, NJ, USA (United States)

Dana-Farber Cancer Institute

Abbott Fund

Justin L. Ricker is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, oncology, and pathology.

Top concepts

Publications per year

2000–2017

37

Publications

37

Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)

Madeleine Duvic, Rakshandra Talpur, Xiao Ni et al. · Blood · 2006 · 1.1K citations · Full text

Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia

Marina Konopleva, Daniel A. Pollyea, Jalaja Potluri et al. · Cancer Discovery · 2016 · 1K citations · Full text

Phase IIB Multicenter Trial of Vorinostat in Patients With Persistent, Progressive, or Treatment Refractory Cutaneous T-Cell Lymphoma

Elise A. Olsen, Youn H. Kim, Timothy M. Kuzel et al. · Journal of Clinical Oncology · 2007 · 1K citations

Linifanib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: Results of a Randomized Phase III Trial

Călin Cainap, Shukui Qin, Wen‐Tsung Huang et al. · Journal of Clinical Oncology · 2014 · 623 citations · Full text

Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes

Guillermo Garcia‐Manero, Hui Yang, Carlos E. Bueso‐Ramos et al. · Blood · 2007 · 460 citations

Rows per page

1–5 of 37